Dermavant Sciences

Dermavant Sciences Ltd. is a clinical-stage biopharmaceutical company specializing in medical dermatology therapeutics. The company's lead product candidate, Tapinarof, is a topical cream undergoing Phase III clinical trials for the treatment of psoriasis and atopic dermatitis. Dermavant's pipeline includes additional candidates in various stages of development, such as Cerdulatinib, which targets vitiligo and other inflammatory skin conditions, and Oxybutynin/Pilocarpine, an oral therapy for primary focal hyperhidrosis. Preclinical candidates include DMVT-503, aimed at treating acne vulgaris, and DMVT-501, a potential treatment for atopic dermatitis. Dermavant Sciences has established licensing agreements with several pharmaceutical companies and operates as a subsidiary of Roivant Sciences Ltd. The company, originally known as Roivant Dermatology Ltd., rebranded in June 2016 and is based in London, United Kingdom.